Showing 3741-3750 of 5000 results for "".
- REZOLVE-AD: Monthly and Quarterly Dosing of Rezpegaldesleukin Effective for ADhttps://practicaldermatology.com/news/rezolve-ad-monthly-and-quarterly-dosing-of-rezpegaldesleukin-effective-for-ad/2485647/Results from the blinded 36-week maintenance period showed rezpegaldesleukin demonstrated sustained disease control and new or deepening efficacy in moderate-to-severe atopic dermatitis (AD) with both monthly and quarterly dosing regimens, according to an announcem
- Delgocitinib Improves Patient-Reported Outcomes Across Chronic Hand Eczema Subtypeshttps://practicaldermatology.com/news/delgocitinib-improves-patient-reported-outcomes-across-chronic-hand-eczema-subtypes/2485611/Patient-reported outcome (PRO) data from the phase 3 DELTA 1 and DELTA 2 trials suggest that topical delgocitinib cream provides clinically meaningful symptom relief across major subtypes of chronic hand eczema (CHE), according to a poster from Robert Bissonnette,
- Fever and Abdominal Purpura Linked to IgAV Recurrence in Adultshttps://practicaldermatology.com/news/fever-and-abdominal-purpura-linked-to-igav-recurrence-in-adults/2485592/Systemic corticosteroids and post-bacterial etiology may protect against recurrence or relapse in adult immunoglobulin A vasculitis (IgAV), a new study suggests. Investigators for the retrospective cohort study
- Empowering the HS Community Through Wellness, Nutrition, and Compassionhttps://practicaldermatology.com/news/empowering-the-hs-community-through-wellness-nutrition-and-compassion/2485555/Wellness goes beyond skin when it comes to managing hidradenitis suppurativa (HS). In an effort to spread awareness of that concept, HS Connect founder and CEO Brindley Brooks and COO Cristina Curp took the stage at
- ORKA-001 Phase 1 Data Support Potential Once-Yearly IL-23 Dosinghttps://practicaldermatology.com/news/orka-001-phase-1-data-support-potential-once-yearly-il-23-dosing/2485550/A half-life–extended IL-23p19 monoclonal antibody demonstrated sustained pharmacokinetics and favorable tolerability that may support once-yearly dosing in plaque psoriasis, according to “Phase 1 Clinical Data of ORKA-001, a Novel Half-Life–Extended IL-23p19 Monoclonal Antibody,” a poster by Jame
- Envudeucitinib Enables Durable Treat-to-Target Control in Plaque Psoriasishttps://practicaldermatology.com/news/envudeucitinib-enables-durable-treat-to-target-control-in-plaque-psoriasis/2485542/Envudeucitinib enabled a high proportion of patients with moderate-to-severe plaque psoriasis to achieve and maintain stringent treat-to-target thresholds through one year of therapy, according to “Achievement of Treat-to-Target Thresholds With Envudeucitinib in Moderate-to-Severe Plaque Psoriasi
- Drs. Neal Bhatia and Ted Rosen Present New Therapeutics ‘Popping’ in 2026https://practicaldermatology.com/news/drs-neal-bhatia-and-ted-rosen-present-new-therapeutics-popping-in-2026/2485511/In their annual overview of therapeutics at Maui Derm Hawaii 2026, Ted Rosen, MD, and Neal Bhatia, MD, used a K-Pop Demon Hunters theme to walk through emerging strategies across inflammatory skin diseases. Drs. Rosen and Bhatia emphasized a shift toward non‑steroidal topicals that can be
- Study: Mycophenolate Mofetil Effective as First-Line Option for Juvenile Localized Sclerodermahttps://practicaldermatology.com/news/study-mycophenolate-mofetil-effective-as-first-line-option-for-juvenile-localized-scleroderma/2485505/A new study comparing methotrexate (MTX) and mycophenolate mofetil (MMF) suggests MMF may offer a comparable alternative with better patient-reported tolerability outcomes. Researchers analyzed data from 114 patients (MTX [n=68
- Doxycycline and Minocycline Show Benefit in OLP Gingival Lesionshttps://practicaldermatology.com/news/doxycycline-and-minocycline-show-benefit-in-olp-gingival-lesions/2485468/A retrospective analysis suggests doxycycline and minocycline may offer an effective systemic option for patients with inflammatory oral lichen planus (OLP) involving the gingiva who fail to respond to topical agents. Study res
- No New Safety Signals in Broad Ruxolitinib Dataset, Including AD, Vitiligo, and AAhttps://practicaldermatology.com/news/no-new-safety-signals-in-broad-ruxolitinib-dataset-including-ad-vitiligo-and-aa/2485382/A new safety analysis presented at the 2026 Winter Clinical Dermatology Conference in Maui supporting the long-term tolerability of ruxolitinib cream (Opzelura®, Incyte) in a range of inflammatory skin conditions. The integrat